Evaluation of the efficacy and safety of 10% intravenous immunoglobulin Privigen in real clinical practice

Cover Page
Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract


Relevance. Replacement therapy with human immunoglobulins is the leading pathogenetic method of treatment of primary immunodeficiency with impaired antibody synthesis. Currently, several preparations of human immunoglobulins for intravenous administration are available in Russia. Purposes. Evaluation of the efficacy and safety of Privigen immunoglobulin intravenous 10% liquid in real clinical practice within 12 clinical months. Methods. Twenty adults diagnosed with common variable immunodeficiency or X-linked agammaglobulinemia received intravenous Privigen® infusions (0.2-0.4 mg/kg) at 24±3 intervals over a 12-month period. The primary endpoint was the annual rate of infections and adverse events. Results. Sufficient level of IgG was achieved in most patients during the study. Severe adverse reactions during the treatment were not registered. Conclusions. High efficacy and safety of monthly replacement therapy in patients with primary immunodeficiency with impaired antibody synthesis has been demonstrated.

Full Text

Restricted Access

About the authors

L G Khludova

NRC Institute of immunology FMBA of Russia

Moscow, 115522, Russian Federation

I A Manto

NRC Institute of immunology FMBA of Russia

Moscow, 115522, Russian Federation

Elena A Latysheva

NRC Institute of immunology FMBA of Russia

Email: Ealat@mail.ru
Moscow, 115522, Russian Federation

T V Latysheva

NRC Institute of immunology FMBA of Russia

Moscow, 115522, Russian Federation

M R Khaitov

Moscow, 115522, Russian Federation

References

  1. Picard C, Al-Herz W, Bousfiha A, Casanova JL, Chatila T, Conley ME. Primary immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency 2015. J Clin Immunol. 2015;35(8):696-726. doi: 10.1007/s10875-015-0201-1.
  2. Al-Herz W, Bousfiha A, Casanova JL, Chatila T, Conley ME, Cunningham-Rundles C. Primary Immunodeficiency Diseases: An Update on the Classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency. Front Immunol. 2014;5. doi: 10.3389/fimmu.2014.00162. Available from: https://www. frontiersin.org/articles/10.3389/fimmu.2014.00162/full.
  3. Schäffer A, Salzer U, Hammarström L, Grimbacher B. Deconstructing common variable immunodeficiency by genetic analysis. Curr Opin Genet Dev. 2007;17(3):201-212. doi: 10.1016/j.gde.2007.04.002.
  4. Di Renzo M, Pasqui A, Auteri A. Common variable immunodeficiency: a review. Clin Exp Med. 2004;3(4):211-217. doi: 10.1007/s10238-004-0027-2.
  5. Picard C. Primary Immunodeficiency Diseases: an Update on the Classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency J Clin Immunol. 2015; 35(8):696-726.
  6. Мухина АА, Кузьменко НБ, Родина ЮА, Кондратенко ИВ, Бологов АА, Латышева ТВ. Характеристика пациентов с первичными иммунодефицитными состояниями в Российской Федерации: от рождения до старости. Педиатрия, 2019;98(2):24-31. DOI: 10/241100/0031-403X-2019-98-3-24-31 [Characteristics of patients with primary immunodeficiency states in the Russian Federation: from birth to old age. Mukhina AA, Kuzmenko NB, Rodina YA, Kondratenko IV, Bologov AA, Latysheva TV. Pediatrics. 2019;98(2):24-31 (In Russ.)].
  7. Roifman C, Levison H, Gelfand E. High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease. The Lancet. 1987;329(8541):1075-1077. doi: 10.1016/s0140-6736(87)90494-6.
  8. Eijkhout H, van der Meer J, Kallenberg C, Weening RS, van Dissel JT, Sanders LA. The Effect of Two Different Dosages of Intravenous Immunoglobulin on the Incidence of Recurrent Infections in Patients with Primary Hypogammaglobulinemia. Ann Intern Med. 2001;135(3):165. doi: 10.7326/0003-4819135-3-200108070-00008.
  9. Roifman C, Schroeder H, Berger M, Sorensen R, Ballow M, Backley RH. Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency. Int Immunopharmacol. 2003;3(9):1325-1333. DOI: 10.1016/ s1567-5769(03)00134-6
  10. Chapel H, Cunningham-Rundles C. Update in understanding common variable immunodeficiency disorders (CVIDs) and the management of patients with these conditions. Br J Haematol. 2009;145(6):709-727. doi: 10.1111/j.1365-2141.2009.07669.x.
  11. Cramer M, Frei R, Sebald A, Mazzoletti P, Maeder W Stability over 36 months of a new liquid 10% polyclonal immunoglobulin product (IgPro10, Privigen) stabilized with L-proline. Vox Sang. 2009;96(3):219-225. doi: 10.1111/j.1423-0410.2008.01143.x.
  12. Tankersley D, Preston M, Finlayson J. Immunoglobulin G dimer: An idiotype-anti-idiotype complex. Mol Immunol. 1988;25(1):41-48. doi: 10.1016/0161-5890(88)90088-0.
  13. Roux KH, Tankersley DL. A view of the human idiotypic repertoire. Electron microscopic and immunologic analyses of spontaneous idiotype-antiidiotype dimers in pooled human IgG. J Immunol. 1990;144(4):1387-1395.
  14. Spycher MO, Bolli R, Hodler G, Gennari K, Hubsch A, Spath P, Schnorf J. Well-tolerated liquid intravenous immunoglobulin G preparations (IVIGs) have a low immunoglobulin G dimer (IgG-dimer) content. J Autoimmun. 1999;96(Suppl. 1):96.
  15. Bolli R, Woodtli K, Bartschi M, Hofferer L, Lerch P. L-Proline reduces IgG dimer content and enhances the stability of intravenous immunoglobulin (IVIG) solutions. Biologicals. 2010;38(1):150-157. doi: 10.1016/j.biologicals.2009.09.002.
  16. Sleasman JW, Duff CM, Dunaway T, Rojavin MA, Stein MR. Tolerability of a new 10% liquid immunoglobulin for intravenous use, Privigen, at different infusion rates. J Clin Immunol. 2010;30(3):442-448. doi: 10.1007/s10875-010-9373-x.
  17. Stein MR, Nelson RP, Church JA, Wasserman RL, Borte M, Vermylen C. IgPro10 in PID study group. Safety and efficacy of Privigen, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies. J Clin Immunol. 2009;29(1):137-144. DOI: 10.1007/ s10875-008-9231-2.
  18. Church JA, Borte M, Taki H, Nelson RP, Sleasman JW, Knutsen AP. Efficacy and safety of Privigen in children and adolescents with primary immunodeficiency. Ped Asthma Allergy Immunol. 2009;22(2):53-61. doi: 10.1089/pai.2009.0005.
  19. Robak T, Salama A, Kovaleva L, Vyhovska Y, Davies SV, Mazzucconi MG. Efficacy and safety of Privigen, a novel liquid intravenous immunoglobulin, in adolescent and adult patients with chronic immune thrombocytopenic purpura. Hematology. 2009;14(4):227-236. doi: 10.1179/102453309x439773.
  20. Leger JM, De Bleecker J, Sommer C, Robberecht W, Saarela M, Kamienowski J. Efficacy and safety of Privigen in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study) Journal of the Peripheral Nervous System. 2013;18(2):130-140. doi: 10.1111/jns5.12017.
  21. O’Donnell JL, Roberts-Thomson pJ, Ahem MJ, Bradley J. Alteration in circulating neutrophil CR3 density associated with immunoglobulin infusion. Aust NZ J Med. 1988;18:95-100.
  22. Orbach H, Katz U, Sherer Y, Shoenfeld Y Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol. 2005;29:173-184. DOI: 10.1385/ criai:29:3:173.
  23. Woodruff RK, Grigg AP, Firkin FC, Smith IL. Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients. Lancet. 1986;2(8500):217-218. doi: 10.1016/s0140-6736(86)92511-0.
  24. Sztajzel R, Le Floch-Rohr J, Eggimann P. High-dose intravenous immunoglobulin treatment and cerebral vasospasm: a possible mechanism ofischemic encephalopathy? Eur Neurol. 1999;41:153-158. doi: 10.1159/000008040.

Statistics

Views

Abstract - 24

PDF (Russian) - 0

PlumX

Article Metrics

Metrics Loading ...

Dimensions


Copyright (c) 2019 Russian Allergological Journal

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies